Liquidia says Delaware court ruled claims 1 and 14 of United Therapeutics' '327 patent valid and infringed

Liquidia Corp

District Court for the District of Delaware found claims 1 and 14 of U.S. Patent No. 11,826,327 valid and infringed by Liquidia's YUTREPIA; remaining asserted claims were held invalid
Parties must submit a proposed form of judgment specifying remedies within one week; United Therapeutics (UTHR) has sought injunctive relief restricting YUTREPIA's market availability
CEO Roger Jeffs said Liquidia disagrees and will pursue all appellate options; the company plans an NDA supplement to remove the PH-ILD indication from YUTREPIA's label
Liquidia said it cannot reasonably estimate the range of outcomes or financial exposure; remedies could range from removing the PH-ILD indication to broader restrictions on product availability
Liquidia (LQDA) trades on Nasdaq; YUTREPIA was approved in 2025 for PAH and PH-ILD, and the press release was filed as Exhibit 99.1

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.